Merck Revises FY23 Revenue Guidance To $58.6B-$59.6B Vs. Consensus Of $53.18B And Prior Guidance Of $57.7B-$58.9B, It Forecasts Adjusted EPS Of $2.95-$3.05 Vs. Consensus Of $2.60 And Prior Guidance Of $6.88-$7.00
Portfolio Pulse from Benzinga Newsdesk
Merck has revised its FY23 revenue guidance to $58.6B-$59.6B, up from the prior guidance of $57.7B-$58.9B and above the consensus of $53.18B. The company also forecasts an adjusted EPS of $2.95-$3.05, which is higher than the consensus of $2.60 but lower than the prior guidance of $6.88-$7.00.
August 01, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck's revised FY23 revenue guidance is higher than both the consensus and its prior guidance, which could positively impact its stock price. However, its adjusted EPS forecast is lower than its prior guidance, which could have a negative effect.
Merck's revised revenue guidance for FY23 is higher than both the consensus and its prior guidance, which is a positive signal for investors and could lead to an increase in its stock price. However, the company's adjusted EPS forecast is lower than its prior guidance, which could be seen as a negative signal and could potentially lead to a decrease in its stock price. Therefore, the overall impact on Merck's stock price is expected to be mixed.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100